Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays.
OBJECTIVE
To identify autoantibody signatures in ovarian cancer using protein microarray technology.


METHODS
Protein microarrays were screened using non-malignant peritoneal fluid (n=30) and ascites fluid pooled from ovarian cancer patients (n=30).


RESULTS
Fifteen potential tumour-associated antigens were discovered. AASDHPPT showed the strongest signal-to-noise ratio.


CONCLUSIONS
Protein microarrays are suitable for autoantibody discovery in ovarian cancer but the signatures are of low frequency.
Gunawardana
C Geeth
CG
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 6th Floor, Room m6-201, 60 Murray Street, Toronto, ON, Canada.
Memari
Nader
N
Diamandis
Eleftherios P
EP
D000912:Antibodies, Neoplasm / Q000276:immunology*; D001201:Ascites / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology*; D015153:Blotting, Western; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D009363:Neoplasm Proteins / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology*; D040081:Protein Array Analysis / Q000379:methods*; D015203:Reproducibility of Results
D000912:Antibodies, Neoplasm; D001323:Autoantibodies; D009363:Neoplasm Proteins